Overview

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug;LPX-TI641

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
A Phase I First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Doses of LPX-TI641.
Phase:
Phase 1
Details
Lead Sponsor:
LAPIX Therapeutics Inc.